The sharp revenue drop and widened loss will likely pressure XNCR shares near-term. Key catalysts remain XmAb819 data in 2H26 and XmAb412 trial start in 3Q26. Monitor cash burn trajectory and any partnership milestone updates.
XNCR drugs
XNCR drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $12.31entry
- T+1 · 6mo ago 0.00%α −0.83% · $12.31
- T+5 · 6mo ago +0.57%α −0.94% · $12.38
- T+20 · 6mo ago −7.23%α −10.37% · $11.42
- T+60 · 4mo ago +57.60%α +53.76% · $19.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xencor reported Q1 2026 revenue of $4.5M (down 86% YoY) and a net loss of $128.9M ($1.71 per share), massively missing consensus estimates of a $0.65 loss per share. The quarter lacked milestone revenue that boosted prior-year results, and cash burn remains high, with year-end cash guidance lowered to $380-400M.
Key Financial Metrics
Key Facts
- Q1 2026 revenue fell 86% YoY to $4.5M from $32.7M
- EPS of -$1.71 missed consensus estimate of -$0.65 (-163% surprise)
- Net loss widened to $128.9M from $48.4M in Q1 2025
- Cash and securities decreased to $541.8M from $610.8M at year-end 2025
- Year-end 2026 cash guidance lowered to $380-400M from prior $400-430M
- Pipeline milestones on track (XmAb819 expansion data 2H26, XmAb412 FIH 3Q26)
Financial Impact
Revenue decline of $28.2M YoY; net loss increase of $80.5M; EPS miss of $1.06 vs consensus
Risk Factors
- Lowered cash guidance signals higher than expected burn or delayed milestones
- Dependence on partnership milestones for meaningful revenue
- Clinical trial delays or negative data could further pressure valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001326732-26-000042 |
| Document: xncr-20260506.htm | 0001326732-26-000042 |
| Document: 0001326732-26-000042-index-headers.html | 0001326732-26-000042 |
| Document: 0001326732-26-000042-index.html | 0001326732-26-000042 |
| Document: 0001326732-26-000042.txt | 0001326732-26-000042 |
| 8-K Data (Synthetic) | 0001326732-26-000042 |
Track record
20 reports on XNCR
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers